News
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
News, Pre-Market Outlook, Markets, Movers
Theriva Biologics FY EPS $(1.14) Beats $(1.28) Estimate; As Of December 31, 2023, Theriva Biologics Reports $23.2M In Cash, Which Is Expected To Provide Runway Into The First Quarter Of 2025
25 Mar 24
Earnings, News
Earnings Scheduled For March 25, 2024
25 Mar 24
Earnings
Preview: Theriva Biologics's Earnings
22 Mar 24
Earnings
Theriva Biologics Granted EU Patent #3292142 For "Oncolytic Adenoviruses With Mutations In Immunodominant Adenovirus Epitopes And Their Use In Cancer Treatment"
20 Mar 24
News
Theriva Biologics Announces Positive Recommendation From The Independent Data Monitoring Committee Of VIRAGE, The Phase 2b Clinical Trial Of VCN-01 In Combination With Chemotherapy For Metastatic Pancreatic Ductal Adenocarcinoma
7 Feb 24
Biotech, News, General
Press releases
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
25 Apr 24
News, Press Releases
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers
17 Apr 24
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
8 Apr 24
News, Health Care, Press Releases
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
25 Mar 24
Earnings, Press Releases
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
11 Mar 24
News, Press Releases
Pancreatic Ductal Adenocarcinoma (PDAC) Market to Witness Upsurge in Growth During the Forecast Period (2023-2032) – DelveInsight | Alphamab, AstraZeneca, Cantargia, Elicio, I-Mab Biopharma, Incyte
8 Feb 24
News, Press Releases